BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman Sells 4,151 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 4,151 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $103,775.00. Following the transaction, the chief financial officer now directly owns 116,809 shares of the company’s stock, valued at approximately $2,920,225. This trade represents a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Monday, March 3rd, Troy Wichterman sold 660 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total value of $16,803.60.
• On Wednesday, February 12th, Troy Wichterman sold 159 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total value of $4,219.86.
• On Monday, January 6th, Troy Wichterman sold 987 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total value of $26,668.74.

BioLife Solutions Trading Down 4.6 %

Shares of BLFS stock traded down $1.21 during mid-day trading on Thursday, hitting $25.06. 278,326 shares of the company’s stock were exchanged, compared to its average volume of 349,466. BioLife Solutions, Inc. has a fifty-two week low of $14.84 and a fifty-two week high of $29.55. The stock has a 50-day simple moving average of $26.64 and a two-hundred day simple moving average of $25.51. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -23.64 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. During the same quarter last year, the firm earned ($0.21) earnings per share. Equities analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC acquired a new position in BioLife Solutions in the fourth quarter valued at $26,000. Mark Sheptoff Financial Planning LLC acquired a new position in BioLife Solutions in the third quarter valued at $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in BioLife Solutions in the fourth quarter valued at $31,000. Quest Partners LLC acquired a new position in BioLife Solutions in the third quarter valued at $57,000. Finally, 1620 Investment Advisors Inc. boosted its holdings in BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 675 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. HC Wainwright upped their price target on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Craig Hallum upped their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Benchmark restated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. Northland Securities increased their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. Finally, TD Cowen increased their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.